CPT code 84153 represents the laboratory measurement of total prostate specific antigen (PSA) in serum or plasma. PSA testing is a widely used tool for clinician evaluation of prostate health, including population-level screening discussions and individual patient monitoring for prostate cancer progression or treatment response. As a common clinical chemistry assay, CPT code 84153 is relevant across hospital, outpatient, and independent laboratory settings and factors into both preventive care pathways and oncology monitoring protocols.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for PSA testing, national reimbursement and utilization benchmarks where available, and policy considerations affecting laboratory billing and reporting for this code. The publication also summarizes payer coverage trends, denial drivers, and common documentation points that influence claim adjudication for PSA testing. The content is intended to help billing managers, laboratory directors, and policy analysts understand how CPT code 84153 is used in clinical practice and processed by major payers at a national level.